1052 results about "Ulcerative colitis" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application of the bifidobacterium animalis subsp. Lactis, and belongs to the field of microorganisms. According to the invention, a strain of bifidobacterium anaticum subsp. Lactis LIHUO 01 is screened out, the strain is preserved in the Guangdong Microbial Culture Collection Center on November 20, 2024, and the preservation number is GDMCC No: 65512. The invention also discloses a preparation method of the bifidobacterium anaticum subsp. Lactis strain, and the bifidobacterium anaticum subsp. Lactis strain has the advantages that the bifidobacterium anaticum subsp. Lactis strain can be used for preparing the bifidobacterium anaticum subsp. Lactis strain; the bifidobacterium animalis subsp. Lactis LIHUO 01 has good in-vitro probiotic characteristics, has the effects of relieving ulcerative colitis, improving constipation and regulating intestinal flora, and has a good application prospect in preparation of food or health care products or medicines for relieving ulcerative colitis or improving constipation or regulating intestinal flora.

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention discloses bifidobacterium animalis subsp. Lactis BLa79 as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC (China General Microbiological Culture Collection Center) NO. 32426, and the preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC NO. 32426. Based on the strain, the invention also provides application and related products of the strain. The BLa79 strain has broad-spectrum antibacterial performance, has the function of regulating intestinal flora, can effectively relieve ulcerative colitis, and can relieve colitis by increasing body weight, reducing DAI score, reducing spleen index, inhibiting colonic atrophy, reducing proinflammatory factor level and promoting SIgA secretion.

The invention relates to protein nanoparticles for treating ulcerative colitis as well as a preparation method and application thereof, and relates to the field of nano pharmaceutical preparations. 5-aminosalicylic acid is encapsulated in zein to achieve the purpose of improving the bioavailability of the 5-aminosalicylic acid by preparing protein nanoparticles of a targeted inflammation colon part, mannose grafted hyaluronic acid is used as a stabilizer to be attached to the surfaces of the zein nanoparticles through electrostatic adsorption and hydrogen-bond interaction, and the bioavailability of the 5-aminosalicylic acid is improved. Mannose can be targeted to immune cells through a mannose receptor, and can be cooperated with 5-aminosalicylic acid to treat ulcerative colitis. The hyaluronic acid has the effects of stabilizing the protein nanoparticles and targeting macrophages and intestinal epithelial cell CD44 receptors in ulcerative colitis tissues, so that aggregation of the nanoparticles in the colitis tissues is mediated, the protein nanoparticles have the functions of resisting inflammation, resisting oxidation and repairing barrier injury, and a new research direction is provided for treatment of ulcerative colitis.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The present invention relates to Obefazimod or a pharmaceutically acceptable salt thereof for use in the treatment of ulcerative colitis.

The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention discloses a plant lactobacillus JNL0074 strain, application thereof and a microbial agent, and belongs to the technical field of microorganisms. The lactobacillus plantarum JNL0074 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC NO: 31047, and the lactobacillus plantarum is classified and named as lactobacillus plantarum. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention discloses a strain of lactobacillus pentosus JNL0030, application thereof and a microbial preparation, and belongs to the technical field of microorganisms. The lactobacillus pentosus JNL0030 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO: 31045, and the lactobacillus pentosus is classified and named as lactobacillus pentosus. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention discloses application of polygonatum kingianum polysaccharide in preparation of medicine for treating ulcerative colitis, and relates to the field of biomedicine.The preparation method of the polygonatum kingianum polysaccharide comprises the following steps that S1, polygonatum kingianum roots are taken, smashed and then screened, and polygonatum kingianum powder is prepared; s2, the polygonatum kingianum powder obtained in the step S1 is soaked in an ethanol solution, and polygonatum kingianum powder residues are obtained; s3, performing water extraction on the polygonatum kingianum powder residues obtained in the step S2 to obtain an extracting solution; s4, concentrating the extracting solution obtained in the step S3, adding ethanol into the concentrated solution to precipitate polysaccharide, and centrifugally separating to obtain crude polysaccharide; the polygonatum kingianum polysaccharide disclosed by the invention is high in purity, the effectiveness of the polygonatum kingianum polysaccharide in treatment of ulcerative colitis is verified, and a new solution is provided for relieving the problem of shortage of current colitis treatment medicines.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.

The invention provides a drug-loaded callicarpa nudiflora-derived extracellular vesicle as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The drug-loaded callicarpa nudiflora-derived extracellular vesicle has relatively high encapsulation efficiency and drug loading rate and good gastrointestinal tract stability and biocompatibility, can target a colitis disease part to reduce adverse reaction of a drug and improve the curative effect, solves the problem that the drug is insoluble in water, and can be used for preparing the drug-loaded callicarpa nudiflora-derived extracellular vesicle. The invention provides a novel drug delivery strategy for treating the ulcerative colitis, and is expected to become an effective strategy for clinically treating the ulcerative colitis, thereby achieving the effects of synergistically treating the ulcerative colitis and improving the effectiveness and safety of drug delivery.

The invention discloses a carrier-free nano-particle with pH / ROS dual response as well as a preparation method and application of the carrier-free nano-particle. The preparation method comprises the following steps: enabling quinolizidine alkaloid and flavonol to be subjected to self-assembly, so as to prepare quinolizidine alkaloid-flavonol carrier-free nano particles; modifying the quinolizidine alkaloid-flavonol carrier-free nano particles by adopting a phenylboronic acid-hyaluronic acid conjugate, so as to prepare nano particles modified by the phenylboronic acid-hyaluronic acid conjugate; and coating the surfaces of the nano-particles modified by the phenylboronic acid-hyaluronic acid conjugate with a pH sensitive polymer to prepare the pH / ROS dual-response carrier-free nano-particles. The sophocarpidine-kaempferol carrier-free nanoparticles with pH / ROS dual response, prepared by the invention, have the advantages of good targeting property, high biocompatibility, small toxicity and adverse reaction and the like, meanwhile, the nanoparticles have a good anti-inflammatory effect, and a new choice is provided for the treatment of ulcerative colitis.

The invention relates to the technical field of biological medicines, and particularly discloses application of gambogic acid in preparation of a medicine for treating ulcerative colitis. The gambogic acid provided by the invention can be used for preparing a programmed necrosis inhibitor and a medicine for treating ulcerative colitis, and the gambogic acid is beneficial to improving cell morphology, increasing cell viability and improving symptoms of ulcerative colitis caused by DSS. Chemical structure of gambogic acid: # imgabs0 #

The invention discloses lactobacillus delbrueckii JNL0010, application of the lactobacillus delbrueckii JNL0010 and a microbial agent, and belongs to the technical field of microorganisms. The lactobacillus delbrueckii JNL0010 is preserved in the China General Microbiological Culture Collection Center on June 24, 2024, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC NO: 31042, and the lactobacillus delbrueckii JNL0010 is classified and named as lactobacillus delbrueckii subsp.bulgaricus. The lactobacillus delbrueckii JNL0010 is named as lactobacillus delbrueckii subsp.bulgaricus. The strain can realize high yield of indole-3-lactic acid in an MRS culture medium. An in-vitro experiment result shows that supernate of the strain remarkably inhibits inflammatory polarization of macrophages stimulated by lipopolysaccharide and secretion of inflammatory factors. Animal experiment results show that the strain can significantly inhibit sodium dextran sulfate induced colonic tissue inflammatory factor secretion and intestinal barrier injury, alleviate ulcerative colitis, and show a huge application value.

The invention relates to the technical field of microbial medicines, and particularly discloses Brawler's bacteria EMF75-02B1B and an application of the Brawler's bacteria EMF75-02B1B. The invention discloses Blauria sp. EMF75-02B1B, which is preserved in the Guangdong Microbial Culture Collection Center on September 2, 2024, and the preservation number of the Blauria sp. EMF75-02B1B is GDMCC No: 65084. A mouse model proves that the Brawler bacteria EMF75-02B1B can obviously improve the disease activity index (DAI) of a dextran sodium sulfate induced ulcerative colitis mouse, relieve the weight loss and colon shortening degree of the ulcerative colitis mouse, enhance the intestinal barrier function and relieve inflammatory response.

The invention belongs to the field of spaceflight purple corn RS3 type resistant starch, and particularly relates to spaceflight purple corn RS3 type resistant starch as well as a preparation method and application thereof. The preparation method comprises the following steps: adding water into spaceflight purple corn for blending to obtain starch milk; performing ultrasonic treatment on the starch milk, adjusting the starch milk to be acidic, and gelatinizing to obtain gelatinized starch; pullulanase is added into the gelatinized starch for enzymolysis, high-temperature enzyme deactivation is performed after enzymolysis is completed, then cooling, aging recovery, suction filtration and water washing are performed in sequence, and filter residues are obtained; and drying, crushing and sieving the filter residues. The invention provides a preparation method of spaceflight purple corn RS3 resistant starch, the problem that the prepared RS3 resistant starch is low in content and unstable is solved, and experiments prove that the spaceflight purple corn RS3 resistant starch can reduce the expression of inflammatory factors IL-6 and TNF-alpha in serum, and can reduce the content of the inflammatory factors IL-6 and TNF-alpha by adjusting the proportion of each flora in intestinal flora. Therefore, the steady state of the environment in the intestinal tract is controlled, and the effect of treating ulcerative colitis is achieved.

The present invention provides an application of a thorn sugar neutral polysaccharide in preparing a drug for preventing and / or treating ulcerative colitis, and belongs to the field of medical technology. Animal experimental results show that after the thorn sugar neutral polysaccharide is used in a mouse model of ulcerative colitis, the phenomenon of colon shortening can be alleviated, the production of harmful bacteria can be inhibited, the abundance of Helicobacter genus can be reduced, the number of beneficial bacteria can be increased, and the abundance of Lactobacillus genus, Bacteroides genus and Oscillatory Spirochete genus can be increased. Therefore, the thorn sugar neutral polysaccharide of the present invention can be used as a drug for preparing a drug for preventing or treating ulcerative colitis.

The present invention relates to the technical field of probiotics, and in particular to a strain of Lactobacillus casei ZKLc1221, its lactobacillus and its application in improving ulcerative colitis. Lactobacillus casei )ZKLc1221 has been deposited in the General Microbiology Center of China Microorganism Culture Collection Committee on June 21, 2023, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 27673. The lactobacillus obtained by optimizing the fermentation conditions of Lactobacillus casei ZKLc1221 provided by the present invention has good thermal stability, good effect in improving ulcerative colitis, and can significantly improve pathological damage to the colon.

The invention discloses a Gegen Qinlian decoction vesicle-like nanoparticle as well as an extraction method and application thereof, and belongs to the technical field of biological medicines. The method comprises the following steps: preparing a radix puerariae qinlian decoction stock solution; placing at 4-8 DEG C for 12-15 hours to obtain a gelatinous substance; carrying out low-speed centrifugation at 4-8 DEG C, and taking supernate, so as to obtain crude extract of the vesicle-like nanoparticles of the radix puerariae, radix scutellariae and rhizoma coptidis decoction; carrying out ultracentrifugation at 4-8 DEG C, discarding the supernatant, and carrying out PBS resuspension precipitation to obtain a crude product of the vesicle-like nano-particles of the Gegen Qinlian decoction; and centrifuging 16000g at the temperature of 4-8 DEG C for 10-15 minutes, taking supernate, and filtering by using a 0.22 mu m filter membrane, so as to obtain the vesicle-like nanoparticles of the Gegen Qinlian decoction. According to the Gegen Qinlian decoction vesicle-like nanoparticles as well as the extraction method and the application thereof, the bioavailability and the targeting property of effective components in the Gegen Qinlian decoction are remarkably improved through a nanocrystallization technology, the concentration of the medicine at the ulcerative colitis part is enhanced, and the treatment effect is effectively improved.

The invention belongs to the field of microorganisms. The invention provides an application of a probiotic composition in preparation of medicines for preventing and treating ulcerative colitis, the probiotic composition comprises a combination of bacillus coagulans and clostridium butyricum, and the combination of bacillus coagulans and clostridium butyricum comprises a combination of bacillus coagulans and clostridium butyricum. The bacillus coagulans is bacillus coagulans JSSW-LA-07-1 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.10182, and the clostridium butyricum is clostridium butyricum JSIM-MCB20040312 with the preservation number of CGMCC No.1647. The bacillus coagulans and the clostridium butyricum are used for preparing the bacillus coagulans and the clostridium butyricum. The probiotic composition has the capacity of preventing and treating ulcerative colitis, the ulcerative colitis treating effect is better than that of positive control medicine salazosulfapyridine, the obvious ulcerative colitis treating effect is achieved, the inflammatory factor content and the oxidative stress level are remarkably reduced, inflammatory cell infiltration is reduced, intestinal flora imbalance is improved, and the effect of preventing and treating ulcerative colitis is achieved. Meanwhile, the effect of promoting planting of probiotics is achieved.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

The present invention discloses a black chicken liver hydrolyzed peptide that can be used to improve ulcerative colitis, and its preparation method and application, which belong to the field of biomedicine technology. The preparation method of the black chicken liver hydrolyzed peptide comprises the following steps: making black chicken liver into minced meat and mixing it with water, heating the obtained liquid material, adding alkaline protease for enzymatic hydrolysis, inactivating the enzyme and collecting the supernatant by centrifugation, and freeze-drying to obtain the black chicken liver hydrolyzed peptide. The present invention adopts formaldehyde titration to detect the degree of hydrolysis, adopts SDS-PAGE electrophoresis and Tricine-SDS-PAGE electrophoresis to detect the molecular weight, performs sequence analysis by LC-MS / MS, uses a database to predict the biological function of peptide segments, detects the antioxidant and blood pressure lowering ability of black chicken liver peptide by in vitro experiments, and detects the effect of black chicken liver peptide in improving colitis by mouse experiments. The results show that the black chicken liver peptide prepared by the present invention has the advantages of antioxidant, blood pressure lowering and improvement of ulcerative colitis.

The invention belongs to the technical field of medical auxiliary diagnosis, and discloses an ulcerative colitis virtual biopsy method and system based on a multi-modal image, and the method comprises the steps: building an ulcerative colitis medical image database; constructing a prediction data set according to the extracted quantitative features and the pathological grades of the ulcerative colitis patients; based on the prediction data set, constructing and training an ulcerative colitis virtual biopsy model; and acquiring new clinical data of a patient with ulcerative colitis in real time, inputting the acquired new clinical data into the trained ulcerative colitis virtual biopsy model, and outputting a pathological grading result of ulcerative colitis through extraction and prediction of pathological features. According to the method, automatic analysis of image and endoscopic image features of the lesion area can be realized, the pathological activity state of the ulcerative colitis patient can be accurately judged, and association with long-term prognosis of the patient is established, so that help is provided for clinicians to formulate an individualized UC treatment scheme.

The invention provides an Akkermann Amuc1100 protein mutant as well as a preparation method and application thereof, wild Akkermann Amuc1100 protein is subjected to mutation modification through a molecular biological technical means, and the bioactivity of the Amuc1100 protein mutant subjected to molecular modification is obviously improved compared with that of the wild protein; compared with a wild type Amuc1100 protein, the wild type Amuc1100 protein has a better effect when being applied to the aspects of regulating intestinal immunity, relieving acute pancreatitis, promoting browning of white adipose cells, inhibiting obesity, relieving ulcerative colitis and the like, and a very good application prospect is provided for developing bioactive medicines with higher efficiency.

The invention belongs to the technical field of drug delivery, and particularly relates to a multi-response colitis disease targeting hydrogel microsphere as well as a preparation method and application thereof. The hydrogel microsphere comprises a calcium ion cross-linked sodium alginate microsphere and HA-Cys / Cur NPs which is encapsulated in the calcium ion cross-linked sodium alginate microsphere, the preparation method comprises the following steps: self-assembling cysteine ethyl ester modified hyaluronic acid and curcumin to form nano-particles, encapsulating HA-Cys / Cur NPs into sodium alginate microspheres by an emulsification method, and carrying out calcium ion crosslinking, so as to obtain the hydrogel. The hydrogel microspheres have pH and GSH response characteristics and hyaluronic acid-mediated active targeting capability, are stable in a gastric acid environment, are accurately released at a colon part and target macrophages at an inflammation part, and NPs disconnects disulfide bonds and releases curcumin in an intracellular high GSH environment, so that synergistic treatment of anti-inflammation, anti-oxidation and intestinal mucosa repair is realized, and the curative effect is good. The medicine has a good application prospect in treatment of ulcerative colitis.